DRUG · Unmapped registry intervention
RC48
Find medicine records ·
Find other trials using this name
Clinical trial
RC48 Monotherapy or Combination With Envafolimab for CDK12 Alterations mCRPC With Standard Treatment Failure
NCT06663007
Drugs and interventions used in this trial
2 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
DRUG · Unmapped registry intervention
Envafolimab
Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Study at a glance
Registry-backedRC48 Monotherapy or Combination With Envafolimab for CDK12 Alterations mCRPC With Standard Treatment Failure
Design: INTERVENTIONAL · Status: RECRUITING · Phase: PHASE1, PHASE2
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Prostate Cancerverified · MONDO: prostate cancer
CDK12 Gene Mutationunresolved
Interventions
RC48DRUG
EnvafolimabDRUG
Sponsors & collaborators
Tianjin Medical University Second Hospitallead sponsor
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT06663007 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.